XML 31 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8
General (Details) (USD $)
In Thousands, except Share data, unless otherwise specified
 1 Months Ended 9 Months Ended
Jul. 17, 2013
Nov. 21, 2012
Nov. 21, 2011
Sep. 30, 2014
Related Party Transaction [Line Items]        
License Agreement Terms      
License agreement between the Company and NIH remains in effect, a nonrefundable minimum annual royalty fee and potential future royalties of 4.0% to 5.5% on net sales.
Maximum [Member]
        
Related Party Transaction [Line Items]        
Payment for milestone       $ 500
Minimum [Member]
        
Related Party Transaction [Line Items]        
Payment for milestone       25
Percentage of voting power       50.00%
Eye-Fite Ltd [Member]
        
Related Party Transaction [Line Items]        
Shares issued for acquired outstanding shares     8,000,000  
Additional funds in consideration for issuing common Stock     3,330  
Percentage of diluted issued and outstanding share capital     87.00%  
Stock issuance expenses paid in cash     333  
Shares issued, Price per share     $ 5.148  
Can-Fite [Member]
        
Related Party Transaction [Line Items]        
Common stock shares issued     646,776 466,139
Common stock value issued       2,400
Shares issued, Price per share       $ 0.001
Ordinary shares received       714,922
Percentage of issued and outstanding share capital on Closing Date       7.00%
Ordinary shares sold for considertion 268,095      
Total consideration received for sale of stock 511      
Ordinary shares held       446,827
Percentage of issued and outstanding share capital   12.50%   2.40%
Exercise price of the warrants       $ 7.74
Warrants exercisable period       5 years
Recapitalization transaction description       Every four shares of Common Stock purchased by the New Investors and Can-Fite, they received nine warrants to acquire two share of Common Stock of the Company.
Accrual clinical trials cost       175
Percentage of sublicensing revenues       20.00%
Percentage of expenses       15.00%
Future additional payments percentage       2.50%
Common Stock converted to additional payment       480,022
Interest rate on deferred payments       3.00%
Deferred payments       2,002
Ophthalix [Member]
        
Related Party Transaction [Line Items]        
Common stock shares issued       97,113
Shares issued, Price per share       $ 5.148
Equity method investment additional amount       $ 500